StockData
Journey Medical Corp logo

Journey Medical Corp (DERM) company profile

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)

Close on Nov 13, 2026Market cap $122.21MP/E –Yield –

About Journey Medical

Pharmaceutical Preparations, SIC 2834

Journey Medical Corporation is a commercial-stage pharmaceutical company that acquires, develops, and commercializes prescription pharmaceutical treatments for dermatological conditions. The company markets a portfolio of prescription products targeting diseases such as rosacea, severe acne, primary axillary hyperhidrosis, fungal skin infections, and wound care, with major brands including Emrosi, Qbrexza, Accutane, Amzeeq, and Zilxi. Its primary customers are specialty pharmacies, independent wholesalers, and distributors, which subsequently supply medications to retail pharmacy chains, independent pharmacies, and managed care organizations.

The company generates substantially all of its product revenues within the United States, alongside supplying select products to international partners such as Cutia Therapeutics in the People's Republic of China. Its distribution network encompasses more than 600 specialty pharmacies and wholesalers nationwide, supported by an internal commercial workforce of 58 full-time employees. Journey Medical Corporation is headquartered in Scottsdale, Arizona.

Summary of the business section of Journey Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
Journey Medical Corp
Founded
2014
Headquarters
Scottsdale, AZ
Address
9237 E Via De Ventura Blvd., Suite 105 85258
Phone
(480) 434-6670
Employees
58, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Short Hills, New Jersey

Stock & identifiers

Ticker
DERM
Exchange
Nasdaq
IPO date
Nov 12, 2021
Shares outstanding
28M, Aug 11, 2026
Public float
$84.66M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1867066
CUSIP
48115J109
ISIN
US48115J1097
FIGI
BBG00ZWVDRK2
Share class FIGI
BBG00ZWVDRL1
EIN
47-1879539

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Claude MaraouiPresident & CEO, Director2,435,990
Ramsey AlloushChief Operating Officer598,543
Joseph BeneschCFO261,371
Miranda Jayne ToledanoDirector168,618
Justin Adam SmithDirector231,618
Neil HerskowitzDirector168,618
Michael Cooper PearceDirector67,173
Lindsay A. Rosenwald MdDirector397,616

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Claude Maraoui
President and Chief Executive Officer
$583.50K$310.94K$404.71K$352.74K$14.00K$1.67M-36%
Ramsey Alloush
Chief Operating Officer, Corporate Secretary and General Counsel
$392.95K$295.71K$306.50K$185.04K$14.00K$1.19M-24%
Joseph Benesch
Chief Financial Officer
$318.27K$182.40K$204.32K$114.32K$4.36K$823.67K-30%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 18, 2026, we had 58 employees, all of whom are full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?